Morocco AMMPS Medical Device Establishment Teardown: 171 Declared Entities
An analysis of Morocco's AMMPS list of 171 declared medical device establishments, exploring why MNCs enter via local partners and Law 10.22 changes.
The Shift to an Autonomous Regulator: Law No. 10.22 and the Rise of AMMPS
Morocco's medical device and pharmaceutical sectors are undergoing a historic institutional restructuring. Historically, the Directorate of Medicines and Pharmacy (Direction du Médicament et de la Pharmacie, DMP)—operating as a department under the Ministry of Health and Social Protection—served as the regulator for medical devices, pharmaceuticals, and cosmetics.
However, to resolve administrative bottlenecks, accelerate product registration queues, and strengthen post-market surveillance, the Moroccan government enacted Law No. 10.22. This landmark legislation established the Moroccan Agency for Medicines and Health Products (Agence Marocaine du Médicament et des Produits de Santé, AMMPS) as an independent, autonomous public agency.
AMMPS is governed by a Board of Directors that includes representatives from the Ministry of Health, the Ministry of Finance, the Ministry of Industry and Trade, and is chaired directly by the Head of Government (the Prime Minister). This high-level political backing reflects the agency's mandate to reform Morocco's healthcare supply chain. The first Board of Directors meeting of AMMPS was presided over by the Prime Minister in March 2025, and by 2026, the agency has become fully operational, taking over all regulatory, inspection, and licensing powers from the former DMP. One of the primary instruments AMMPS uses to control the domestic supply chain is the official registry of declared medical device establishments.
This teardown provides a quantitative analysis of the AMMPS declared establishment list (dated April 30, 2026), detailing the domestic-vs-multinational structure of the market, identifying the corporate forms that dominate the channel, and offering strategic guidance for international medical device and IVD manufacturers planning market entry or distributor transitions.
The Establishment Register: 171 Unique Declared Operators
Unlike Algeria’s heavy, inspection-gated import-establishment licensing model, Morocco utilizes a lighter activity declaration model for economic operators. Under Moroccan law, any local company engaged in the importation, distribution, storage, exportation, or maintenance of medical devices must declare its activities to the health administration and obtain a declaration certificate before operating.
An analysis of the official AMMPS registry (dated April 30, 2026) reveals the following profile:
- Total Declared Establishment Records: 176
- Unique Active Entities: 171
- Duplicate Records: 5 excess listings across 4 establishments (on pages 1, 2, 3, and 4)
The duplicates in the registry represent companies that are listed multiple times under slightly different spelling variations or for distinct sites, including:
- Diacare Maroc (Sequence numbers 31 & 32 on Page 1)
- Géant Médical (Sequence numbers 45 & 46 on Page 2)
- Metec Diagnostic SARL (Sequence numbers 103 & 104 on Page 3)
- Promedic SARL (Sequence numbers 142, 143, & 144 on Page 4)
This consolidated list of 171 unique companies represents the entire legal infrastructure for medical device distribution, importing, and warehousing in Morocco. With imports satisfying between 85% and 90% of Morocco’s medical device demand, these 171 entities are the primary gateways for foreign MedTech companies entering the market.
Multinational Entry Strategies: The local partner model
One of the most striking findings from a structural analysis of the AMMPS registry is the absolute dominance of domestic companies. Out of the 171 unique declared establishments, only a handful are direct subsidiaries of global medical device multinationals.
The visible multinational subsidiaries declared on the official list include:
- 3M Maroc: The Moroccan subsidiary of the US-headquartered diversified science and healthcare giant.
- Paul Hartmann: The local entity of the German medical and hygiene manufacturer.
- Alcon Maroc: The local subsidiary of the Swiss-headquartered eye care multinational.
- Fresenius Medical Care: Declared under two distinct regional entities:
- Fresenius Medical Care Pharma Afrique
- Fresenius Medical Care Nord-Ouest et Centre Afrique
The remaining 97% of the registry consists of local, Moroccan-owned distribution companies and SMEs.
Why Multinationals Enter via Local Partners
This database profile provides empirical proof of a key market characteristic: multinational medical device companies overwhelmingly choose to enter Morocco through local distributors (License Holders) rather than establishing their own local corporate subsidiaries.
This partner-centric model is driven by three main factors:
- Registration Ownership Limitations: Under AMMPS guidelines, a foreign manufacturer cannot hold a product registration directly. The registration certificate must be held by a local Moroccan entity, known as the License Holder or local representative. Opening a direct subsidiary is expensive and time-consuming, leading most companies to delegate registration ownership to a trusted local distributor.
- Local Procurement and Hospital Tender Networks: A significant portion of Morocco's medical device market is driven by public sector tenders issued by the Ministry of Health, university hospitals (CHUs), and military medical channels. Bidding on these tenders requires deep, localized knowledge of procurement procedures, native Arabic/French communication, and established commercial networks. Local distributors are far better positioned to navigate these local systems than foreign-managed subsidiaries.
- Logistical Complexity and Post-Market Service: Importers must comply with strict customs requirements, including obtaining a "negative certificate" and proving compliance with ISO 13485 standards. Local distributors manage these logistics, absorb import duties, and provide mandatory technical service and maintenance for active medical equipment.
Corporate-Form Analysis: Domestic LLCs Form the Backbone
A heuristic analysis of the suffixes and names within the 171 unique declared establishments highlights the domestic, private-SME nature of the Moroccan channel.
The breakdown of corporate forms based on legal suffixes reveals:
- SARL / S.A.R.L. (Société à Responsabilité Limitée): 53 unique entities (31.0% of the registry).
- SA / S.A. (Société Anonyme): 3 unique entities (1.8% of the registry).
- No Legal Suffix in Registry Name: 115 unique entities (67.3% of the registry).
The Significance of the SARL Domination
In Morocco, the SARL is the corporate form of choice for small and medium-sized private businesses. It requires minimal capital and can be managed by one or more directors. The fact that nearly a third of all declared medical device companies explicitly carry the SARL suffix—combined with the fact that the vast majority of the "no suffix" entities are also registered as private LLCs—confirms that the Moroccan device channel is highly fragmented and consists of small-to-medium-sized private distributors.
For international manufacturers, this fragmentation means that:
- A single distributor is unlikely to cover all medical specialties. A distributor that is strong in orthopedics (such as Promedic SARL) may have no presence in cardiology, oncology, or diagnostic imaging (where Metec Diagnostic SARL or Géant Médical are prominent).
- Manufacturers must often adopt a multi-distributor strategy, appointing different exclusive partners for specific product lines or separate territories (e.g., separating the public hospital tender market from the private clinic market).
- Due diligence is critical. Since most partners are private SMEs, manufacturers must audit their financial health, warehouse capacities, and regulatory teams to ensure they can sustain a multi-year product lifecycle.
The Role of Joint-Stock Companies (S.A.)
The 3 S.A. (Société Anonyme) entities represent the largest local players. An S.A. in Morocco requires a minimum share capital of 300,000 MAD (approx. USD 33,000) if it does not offer public shares, or 3,000,000 MAD (approx. USD 330,000) if it is publicly listed. These companies feature a formal board of directors (Conseil d'Administration) or a supervisory board (Directoire et Conseil de Surveillance).
These large S.A. entities typically have direct import-export lines, advanced warehouse facilities, and a dedicated team of clinical specialists. However, because they are large organizations, smaller foreign manufacturers may find it difficult to negotiate favorable distribution terms or ensure active marketing focus for their products.
Technical Specifications: The AMMPS Establishment Declaration Checklist
To operate legally in Morocco, local medical device economic operators must complete a formal declaration file with AMMPS. This process verifies that the local company has appropriate facilities, qualified staff, and basic QMS controls.
The mandatory declaration dossier includes the following documents:
- Administrative & Corporate Files:
- The formal establishment declaration form (Déclaration d'Établissement), specifying the activities performed (importation, distribution, storage, maintenance, or export).
- A certified copy of the company's Articles of Association (Statuts).
- A certified copy of the Commercial Register (Registre du Commerce), which must list the medical device distribution and import activity codes.
- A certified copy of the patent tax certificate (Patente) and the tax identification card.
- Facility & Operational Dossier:
- The property deed or lease agreement for the storage facility.
- Detailed architectural floor plans of the warehouse showing separate zones for reception, storage, quarantine, and packaging.
- A detailed description of the security systems, fire prevention measures, and temperature control equipment.
- A copy of the facility's Quality Manual aligned with ISO 13485 standards.
- Responsible Pharmacist Dossier:
- A certified copy of the designated Responsible Pharmacist's (Pharmacien Responsable) diploma.
- Proof of registration of the pharmacist with the National Council of the Order of Pharmacists (Conseil National de l'Ordre des Pharmacien, CNOP) in Morocco.
- The formal appointment letter of the Responsible Pharmacist, signed by the company's legal representative.
- A certified copy of the pharmacist's national identity card.
The Role of the Responsible Pharmacist (Pharmacien Responsable)
Under Moroccan Health Law (specifically the Pharmacy Code), every declared medical device establishment must employ a full-time, designated Responsible Pharmacist (Pharmacien Responsable). The pharmacist is not merely an administrative employee; they have personal, professional, and legal liability for the quality and safety of all medical devices handled by the establishment.
The key responsibilities of the Responsible Pharmacist include:
- Quality Management System (QMS) Oversight: Implementing and maintaining a QMS aligned with ISO 13485 standards, ensuring that all storage conditions (such as temperature and humidity) are monitored, documented, and calibrated annually.
- Batch Release Control: Checking and signing off on every imported shipment of medical devices, verifying that the products match the AMMPS registration certificates and that no damage occurred during transport.
- Vigilance and Incident Reporting: Serving as the official liaison with AMMPS for post-market surveillance, tracking local clinical complaints, and reporting adverse events.
- Audits and Inspections: Managing internal quality audits and serving as the primary point of contact during physical inspections of the warehouse by AMMPS regulatory officers.
Manufacturers must ensure that their chosen distributor has an active, qualified Responsible Pharmacist on staff. If the pharmacist resigns, the establishment's declaration certificate can be suspended until a replacement is formally appointed and approved by AMMPS.
Post-Market Surveillance (PMS) and Vigilance Reporting Timelines
Morocco is aligning its regulatory framework with EU-MDR expectations, placing a strong emphasis on post-market surveillance. Under the AMMPS regime, both the local License Holder and the foreign manufacturer are responsible for post-market vigilance.
Vigilance Reporting Timelines
Morocco mandates strict timelines for reporting adverse events or malfunctions to the AMMPS:
- Critical Public Health Threats: Any event that poses an immediate threat of death or serious injury, or represents a critical public health hazard, must be reported to AMMPS immediately, and no later than 2 calendar days after the License Holder becomes aware of the event.
- Serious Adverse Events: Any event that led to death, serious injury, or a significant deterioration in a patient's health status must be reported within 10 calendar days.
- Standard Malfunctions / Non-Serious Incidents: Technical malfunctions or packaging anomalies that did not lead to serious injury but could recur must be reported within 15 calendar days.
Mandatory PSURs and PMS Plans
For higher-risk devices (Class IIb and Class III), manufacturers must prepare a Periodic Safety Update Report (PSUR) at regular intervals (typically annually for Class III, and at least once every two years for Class IIb). The PSUR must summarize all post-market data, details of any recall actions, and an updated risk-benefit assessment, which must be submitted to AMMPS upon request or during registration renewal.
License Holder Transfer and Distributor Transition Mechanics
One of the greatest operational risks for a MedTech company in Morocco is a "registration lock-in" caused by a dispute with their local representative. Because the local distributor holds the AMMPS registration certificate in their name, terminating a distributor contract can halt sales if the transfer of the registration is not managed correctly.
The Transfer Protocol
To transfer an active registration to a new distributor, AMMPS requires:
- A formal Waiver Letter (Lettre de Désistement) signed, stamped, and notarized by the current License Holder, stating they voluntarily surrender their registration rights for the specific product dossiers.
- A new application dossier submitted by the new distributor, including their valid AMMPS establishment declaration and a new representation agreement.
- Payment of the administrative transfer fee.
Mitigating Hostage Risks
If the distributor refuses to sign the waiver letter due to a contractual dispute:
- The manufacturer cannot import products through the new distributor until the old registration certificate expires (up to 5 years).
- AMMPS will not intervene in commercial disputes, leaving the registration locked.
To protect their business, manufacturers must include mandatory transfer clauses in their initial contracts. These clauses should state that:
- The distributor agrees to sign the AMMPS waiver letter within 7 business days of contract termination.
- Failure to sign the waiver will trigger substantial daily financial penalties.
- The manufacturer retains the right to bypass the waiver if they can present a final, binding arbitration decision or court ruling showing the contract was terminated for cause.
Morocco’s Activity-Declaration Model vs. Algeria’s Import-Licensing Model
Morocco and Algeria operate under fundamentally different regulatory models. The table below outlines the primary operational differences:
| Parameter | Morocco (AMMPS) | Algeria (MIPH / ANPP) |
|---|---|---|
| Primary Model | Activity Declaration Model: Local establishments self-declare their operations to AMMPS and receive an activity certificate. | Import Licensing Model: Importers must obtain an Agrément from the MIPH before they can import devices. |
| Product Registration Fee | 1000 MAD (~USD 111) for medical devices; 500 MAD (~USD 56) for IVDs. | Variable fees based on the dossier type and class. |
| Operator License Validity | Indefinite (subject to warehouse inspections and QMS maintenance). | 2 Years (Decree No. 24, requires inspection for renewal). |
| Regulatory Agency | AMMPS: An autonomous agency chaired by the Prime Minister (Law No. 10.22). | ANPP (product registration) and MIPH (importer licensing). |
| Distributor Transition | Relatively straightforward if a waiver letter is signed. | Highly complex; registration is tightly linked to the initial importer. |
Strategic Local-Representative Selection Workflow
To establish a compliant and resilient market entry in Morocco, manufacturers should implement the following step-by-step process:
- Identify Potential Representative: Screen Moroccan medical distributors based on their product portfolio, clinical sales force, and presence in key cities (such as Casablanca, Rabat, and Fes).
- Verify AMMPS Declaration: Request the distributor's formal AMMPS establishment declaration certificate to confirm they are registered to import and store medical devices.
- Confirm QMS and Facility Compliance: Perform a desk audit of their QMS manual and confirm their warehouse holds ISO 13485 certification.
- Confirm the Responsible Pharmacist Status: Verify the credentials and CNOP registration of the distributor's full-time Pharmacien Responsable.
- Negotiate Registration Ownership and Transfer Clauses: Ensure the distribution contract contains explicit, legally binding clauses governing the transfer of the AMMPS registration certificate upon termination.
- Submit Product Registration Dossier: Prepare the technical file (including CE mark/FDA clearance and ISO 13485) for AMMPS submission through your local representative.
- Monitor Post-Market Surveillance: Establish a communication protocol between your global regulatory team and the local pharmacist to handle vigilance reporting and PSUR updates.
Sibling Maghreb Comparison: Morocco vs. Algeria vs. Tunisia
To help regional business development managers allocate budgets and plan launch timelines, the following table compares the regulatory frameworks of the Maghreb countries:
| Feature / Metric | Morocco (AMMPS) | Algeria (ANPP / MIPH) | Tunisia (DPM / ANMPS) |
|---|---|---|---|
| Market Size (Est. 2025) | ~USD 236 Million | ~USD 350 Million | ~USD 120 Million |
| Import Dependence | 85% to 90% | 90%+ | 90%+ |
| Primary Regulator | AMMPS (Independent Agency) | ANPP (Product) & MIPH (Operator) | DPM & ANMPS (Transitioning) |
| Registration Timeline | 120 days (MD) / up to 12 months (IVD) | Case-by-case | 30 days–16 weeks (official) |
| Registration Fee | ~USD 111 (MD) / ~USD 56 (IVD) | Variable (Dossier-dependent) | Varies |
| License Holder Transfer | Allowed (requires AMMPS transfer file) | Difficult (requires previous holder's waiver) | Moderate (requires DPM approval) |
| Quality Audit Required | Desk audit of ISO 13485 | Desk audit + Importer physical audit | Desk audit |
Frequently Asked Questions
How many medical-device establishments are declared with AMMPS in Morocco?
As of the April 30, 2026 registry update, there are 176 declared medical device establishment records, representing 171 unique corporate entities declared to the Moroccan Ministry of Health and AMMPS.
Do I need a local Moroccan distributor or License Holder to register a medical device?
Yes. Foreign manufacturers cannot register products directly in their own name. You must appoint a declared local Moroccan representative (distributor or regulatory consultant) who will hold the registration certificate as the License Holder and manage importation, customs clearance, and vigilance reporting.
What is the difference between Morocco's AMMPS declaration model and Algeria's MIPH import-license model?
Morocco requires local companies to self-declare their economic activities (import, storage, distribution) to AMMPS to obtain a business-level activity certificate. Algeria requires importers to obtain a specific Agrément (Import Authorization) from the MIPH, which is valid for only two years and requires a pre-license physical facility inspection.
What are Morocco's medical-device registration fees and how long is the certificate valid?
Morocco charges a flat fee of 1000 MAD (~USD 111) per medical device registration and 500 MAD (~USD 56) per IVD registration. The registration certificate is valid for 5 years from the date of issue.
Strategic Summary for Market Entry
Morocco’s medical device sector offers a clear and structured pathway for international manufacturers. The transition of regulatory oversight from the old DMP to the autonomous AMMPS under Law No. 10.22 has brought increased transparency and efficiency, but it also means that compliance enforcement is tightening.
To maximize your chances of commercial success:
- Select the Right Distributor Mix: Since the registry of 171 unique declared establishments is dominated by local private SARL entities, do not expect a single partner to cover all specialties or regions. Evaluate prospective partners' existing portfolios to ensure a strong fit.
- Audit QMS and Storage Compliance: Ensure your local representative holds a valid ISO 13485 certificate and has declared all storage and distribution sites to AMMPS. Moroccan customs require proof of AMMPS compliance for import clearance.
- Draft Clear Transfer Clauses: Since the local representative holds the product registration, always include clear, legally binding clauses in your distributor agreements that govern the transfer of the registration certificate if you decide to change local partners.
By working with compliant local partners and aligning your technical dossiers with EU-MDR standards, you can establish a strong, compliant commercial presence in Morocco, opening doors to the wider North African region.
Disclaimer: This analysis is based on the official register of declared medical device establishments published by the Moroccan Agency for Medicines and Health Products (AMMPS) on April 30, 2026. Regulatory requirements are subject to change. Manufacturers should consult with qualified local regulatory affairs counsel before signing distributor agreements or submitting product dossiers.
For cross-Maghreb regulatory contexts, see our North Africa medical device registration: Morocco, Algeria & Tunisia guide. Sibling country register analyses are available at the Tunisia DPM medical device registry analysis and Egypt EDA medical device register analysis.